These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2859279)

  • 41. Legal liability with psychotropic drug use: extrapyramidal syndromes and tardive dyskinesia.
    Mills MJ; Eth S
    J Clin Psychiatry; 1987 Sep; 48 Suppl():28-33. PubMed ID: 3624218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes.
    Lal S; Bloom D; Silver B; Desjardins B; Krishnan B; Thavundayil J; Thompson T
    J Psychiatry Neurosci; 1993 Jul; 18(4):173-7. PubMed ID: 8104031
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of inpatient depot antipsychotic prescribing.
    Pabis DJ; Dorson PG; Crismon ML
    Ann Pharmacother; 1996 Dec; 30(12):1381-6. PubMed ID: 8968447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extrapyramidal side effects of antipsychotic medications.
    Harris E
    Am J Nurs; 1981 Jul; 81(7):1324-8. PubMed ID: 6113762
    [No Abstract]   [Full Text] [Related]  

  • 45. Drug-induced dystonia.
    Swett C
    Am J Psychiatry; 1975 May; 132(5):532-4. PubMed ID: 1119613
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication.
    Avorn J; Monane M; Everitt DE; Beers MH; Fields D
    Arch Intern Med; 1994 May; 154(10):1113-7. PubMed ID: 7910451
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug-induced dystonia in young and elderly patients.
    Addonizio G; Alexopoulos GS
    Am J Psychiatry; 1988 Jul; 145(7):869-71. PubMed ID: 2898212
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evolutionary origin of extrapyramidal disorders in drug-treated mental patients, its significance, and the role of neuromelanin.
    Forrest FM
    Adv Biochem Psychopharmacol; 1974; 9(0):255-68. PubMed ID: 4151764
    [No Abstract]   [Full Text] [Related]  

  • 51. Neuroleptic drug-induced changes in platelet levels.
    Holt RJ
    J Clin Psychopharmacol; 1984 Jun; 4(3):130-2. PubMed ID: 6145727
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative neurochemical changes associated with chronic administration of typical and atypical neuroleptics: implications in tardive dyskinesia.
    Bishnoi M; Kumar A; Chopra K; Kulkarni SK
    Indian J Exp Biol; 2007 Feb; 45(2):175-9. PubMed ID: 17375557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Drug monitoring in psychiatry].
    Helmchen H; Hippius H; Müller-Oerlinghausen B; Rüther E
    Nervenarzt; 1985 Jan; 56(1):12-8. PubMed ID: 2858063
    [No Abstract]   [Full Text] [Related]  

  • 54. Clinical application of the concept of relative potency: an example involving chlorpromazine and haloperidol.
    Preskorn SH
    J Psychiatr Pract; 2005 Jul; 11(4):258-61. PubMed ID: 16041236
    [No Abstract]   [Full Text] [Related]  

  • 55. Tardive dyskinesia and current dose of neuroleptic drugs.
    Kolakowska T; Williams AO; Ardern M
    Arch Gen Psychiatry; 1986 Jun; 43(6):614. PubMed ID: 2871820
    [No Abstract]   [Full Text] [Related]  

  • 56. Dissimilar dosing with high-potency and low-potency neuroleptics.
    Baldessarini RJ; Katz B; Cotton P
    Am J Psychiatry; 1984 Jun; 141(6):748-52. PubMed ID: 6145357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The pharmacology and therapeutic application of the phenothiazines.
    Rivera-Calimlim L
    Ration Drug Ther; 1977 Apr; 11(4):1-8. PubMed ID: 16316
    [No Abstract]   [Full Text] [Related]  

  • 58. [Abnormal behavior induced by pharmaceutical products].
    Matsuo K
    Chudoku Kenkyu; 2012 Sep; 25(3):209-13. PubMed ID: 23057398
    [No Abstract]   [Full Text] [Related]  

  • 59. [Therapeutic profile of haloperidol].
    Schiele B
    Acta Psiquiatr Psicol Am Lat; 1980 Mar; 26(1):72-6. PubMed ID: 6127873
    [No Abstract]   [Full Text] [Related]  

  • 60. [Neuroleptics].
    Rise A
    Tidsskr Nor Laegeforen; 1976 Mar; 96(7):446-7. PubMed ID: 3864
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.